Drugs / Recombinant Hepatitis E Vaccine (Escherichia Coli)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT02964910 | Aug 2016 → Aug 2017 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02417597 | Apr 2015 → May 2016 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT06564116 Comparator | Mar 2023 → Mar 2024 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | Met primary |
| Phase 4 | NCT03168412 Comparator | May 2017 → Jul 2018 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Hepatitis E Vaccine (Escherichia Coli) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02964910 ↗ |
| Known as | Hecolin | “The first recombinant hepatitis E vaccine (Escherichia Coli), Hecolin® (Xiamen Innovax, China), was approved for people aged ≥16 years.” PMID 40690851 ↗ Jul 2025 |
| Modality | Vaccine | “The hepatitis E vaccine, Hecolin®, has been shown to be safe and highly efficacious among healthy adults aged 16-65 years old.” PMID 31262585 ↗ Jun 2019 |
| Route | Intramuscular | “Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.” NCT02417597 ↗ |